1-3 of 3
Allard Kaptein
Close
Sort by
Journal Articles

Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies

Allard Kaptein, Gerjan de Bruin, Maaike Emmelot-van Hoek, Bas van de Kar, Anouk de Jong, Michael Gulrajani, Dennis Demont, Todd Covey, PhD, Diana Mittag, Tjeerd Barf
Journal: Blood
Blood (2018) 132 (Supplement 1): 1871.
https://doi.org/10.1182/blood-2018-99-109973
Published: 2018
Journal Articles

Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1/2 ACE-CL-001 Study

Todd Covey, PhD, Michael Gulranjani, Jean Cheung, Elena Bibikova, Tracy Clevenger, Fanny Krantz, Karen Pan, Kyoko Yamaguchi, Anouk De Jong, Bart Van Lith, Diana Mittag, Raquel Izumi, PhD, John C. Byrd, MD, William G Wierda, MD PhD, Susan M. O'Brien, MD, Richard R. Furman, MD, Allard Kaptein, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1741.
https://doi.org/10.1182/blood.V130.Suppl_1.1741.1741
Published: 2017
Journal Articles

ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

Bonnie K. Harrington, DVM, Michael Gulrajani, BS, Todd Covey, Allard Kaptein, PhD, Bart Van Lith, Raquel Izumi, PhD, Ahmed Hamdy, MBBCh, Roger Glenn Ulrich, PhD, John C Byrd, MD, Brian J Lannutti, PhD, Amy J. Johnson, PhD
Journal: Blood
Blood (2015) 126 (23): 2908.
https://doi.org/10.1182/blood.V126.23.2908.2908
Published: 2015